Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation

Cancer

Volumn 118, Issue 1, 2012, Pages 268-277

  Estrella, Jeannelyn S ^a   Rashid, Asif ^a   Fleming, Jason B ^a   Katz, Matthew H ^a   Lee, Jeffrey E ^a   Wolf, Robert A ^a   Varadhachary, Gauri R ^a   Pisters, Peter W T ^a   Abdalla, Eddie K ^a   Vauthey, Jean Nicolas ^a   Wang, Hua ^a   Gomez, Henry F ^a   Evans, Douglas B ^b   Abbruzzese, James L ^a   Wang, Huamin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

lymph node; margin; pancreatic cancer; stage; survival

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATICODUODENECTOMY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 83855165798     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26243     Document Type: Article

References (44)

1. Altekruse S, Kosary C, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
2. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP,. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008; 9: 99-132. (Pubitemid 351611725)
3. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005; 92: 1372-1381. (Pubitemid 40705002)
4. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502.
5. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009; 20: 1387-1396.
6. Meszoely IM, Wang H, Hoffman JP,. Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: the Fox Chase Cancer Center experience, 1986-2003. Surg Oncol Clin N Am. 2004; 13: 685-696, x. (Pubitemid 39209348)
7. Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology. 2009; 76: 413-419.
8. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495.
9. Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004; 60: 437-443. (Pubitemid 39233462)
10. Roy R, Maraveyas A,. Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist. 2010; 15: 259-269.
11. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L,. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000; 89: 314-327. (Pubitemid 30489879)
12. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J,. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7: e1000267.
13. Kedra B, Popiela T, Sierzega M, Precht A,. Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterology. 2001; 48: 1762-1766. (Pubitemid 34003522)
14. Meyer W, Jurowich C, Reichel M, Steinhauser B, Wunsch PH, Gebhardt C,. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today. 2000; 30: 582-587. (Pubitemid 30489833)
15. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221: 721-731; discussion 731-733.
16. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000; 4: 567-579.
17. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S,. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997; 21: 195-200. (Pubitemid 27053441)
18. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006; 10: 1199-1210; discussion 1210-1211.
19. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000; 73: 212-218. (Pubitemid 30238413)
20. Ozaki H, Hiraoka T, Mizumoto R, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today. 1999; 29: 16-22. (Pubitemid 29058554)
21. Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003; 26: 243-249. (Pubitemid 36384156)
22. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH,. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. 2006; 32: 271-275.
23. Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI,. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006; 32: 37-43.
24. Lim JE, Chien MW, Earle CC,. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237: 74-85. (Pubitemid 36622320)
25. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW,. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004; 91: 586-594. (Pubitemid 38624667)
26. Edge S, Byrd D, Compton C, eds. AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
27. Shimada H, Okazumi S, Shiratori T, Akutsu Y, Matsubara H,. Impact of lymph node involvement in T2 or T3 thoracic esophageal squamous cell carcinoma. Hepatogastroenterology. 2009; 56: 1039-1043.
28. Hsu WH, Hsu PK, Hsieh CC, Huang CS, Wu YC,. The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer. J Gastrointest Surg. 2009; 13: 1913-1920.
29. Chen YJ, Schultheiss TE, Wong JY, Kernstine KH,. Impact of the number of resected and involved lymph nodes on esophageal cancer survival. J Surg Oncol. 2009; 100: 127-132.
30. Celen O, Yildirim E, Gulben K, Berberoglu U,. Prediction of survival in gastric carcinoma related to lymph node grading by the new American Joint Committee on Cancer/Union International Contre le Cancer System or the Japanese system. Eur J Surg Suppl 2003; 588: 33-39. (Pubitemid 36918755)
31. Roder JD, Bottcher K, Busch R, Wittekind C, Hermanek P, Siewert JR,. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer. 1998; 82: 621-631. (Pubitemid 28090271)
32. Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K,. Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008; 55: 2269-2272.
33. Karpeh MS, Leon L, Klimstra D, Brennan MF,. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000; 232: 362-371.
34. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK,. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010; 28: 264-271.
35. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A,. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010; 28: 256-263.
36. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001; 8: 758-765. (Pubitemid 34003323)
37. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103: 1347-1355. (Pubitemid 40410728)
38. Patel PR, Mansfield PF, Crane CH, et al. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007; 110: 989-995. (Pubitemid 47312863)
39. Rohatgi PR, Mansfield PF, Crane CH, et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006; 107: 1475-1482. (Pubitemid 44546906)
40. Kuo LJ, Liu MC, Jian JJ, et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol. 2007; 14: 2766-2772. (Pubitemid 47460637)
41. Berger AC, Watson JC, Ross EA, Hoffman JP,. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004; 70: 235-240; discussion 240.
42. Sierzega M, Popiela T, Kulig J, Nowak K,. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas. 2006; 33: 240-245. (Pubitemid 44470138)
43. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999; 229: 613-622; discussion 622-624.
44. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg. 1998; 228: 508-517. (Pubitemid 30194394)